ino-9012
Vaccineexperimental
Clinical trial activity
11 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02241369)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- BRCA1 Protein · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1
- Ebola Vaccines · Phase 1
- Esophageal Neoplasms · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1
- Hepatitis C, Chronic · Phase 1
- Hepatitis, Chronic · Phase 1
- HIV Infections · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precancerous Conditions · Phase 1
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ino-9012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04367675 | Phase 1 | Sep 30, 2020 | Inovio Pharmaceuticals, University of Pennsylvania |
| NCT04251117 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2020 | Geneos Therapeutics |
| NCT03606213 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2018 | Inovio Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles, University of California, San Francisco |
| NCT03491683 | Phase 1/Phase 2 (Phase 2) | May 31, 2018 | Inovio Pharmaceuticals |
| NCT03502785 | Phase 1/Phase 2 (Phase 2) | May 24, 2018 | Inovio Pharmaceuticals |
| NCT02772003 | Phase 1 | Jul 1, 2016 | Inovio Pharmaceuticals, National Cancer Institute (NCI), Temple University |
| NCT02514213 | Phase 1 | Jul 1, 2015 | Inovio Pharmaceuticals |
| NCT02464670 | Phase 1 | May 1, 2015 | Defense Advanced Research Projects Agency, GeneOne Life Science, Inovio Pharmaceuticals |
| NCT02960594 | Phase 1 | Dec 1, 2014 | Inovio Pharmaceuticals, Mayo Clinic, Thomas Jefferson University, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh, Wayne State University |
| NCT02163057 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Inovio Pharmaceuticals, University of Pennsylvania |
| NCT02241369 | Phase 1 | May 1, 2014 | Inovio Pharmaceuticals, University of Pennsylvania |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals | For profit | 10 | 8 | 2 | 2014 |
| University of Pennsylvania | Academic/Hospital | 4 | 1 | 2 | 2014 |
| Defense Advanced Research Projects Agency | Government | 1 | 0 | 1 | 2015 |
| GeneOne Life Science | For profit | 1 | 0 | 1 | 2015 |
| Geneos Therapeutics | For profit | 1 | 1 | 1 | 2020 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2018 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2014 |
15 organizations
Page 1 / 1